Gastrointestinal Cancer

P1/2, N=94, Recruiting, Deciphera Pharmaceuticals, LLC | Trial completion date: Jun 2027 --> Mar 2029

P=N/A, N=61, Completed, CStone Pharmaceuticals | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Sep 2024

Because no significant bias was identified in this limited cohort, an ancestry-based calibration constant or normalization procedure cannot be systematically applied. However, the TMB calling algorithm used by TSO500 relies upon population databases. Therefore, the underlying variants and calculations used to determine TMB should be manually evaluated on a case-by-case basis, particularly for tumors with TMBs close to treatment thresholds in patients of ancestries underrepresented in population databases.

P1, N=26, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Oct 2024 --> Jun 2025 | Trial primary completion date: Oct 2024 --> Jun 2025

P=N/A, N=500, Recruiting, The Second Affiliated Hospital of Harbin Medical University; The Second Affiliated Hospital of Harbin Medical University

P=N/A, N=60, Completed, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University o

P=N/A, N=10000, Not yet recruiting, The First Affiliated Hospital of Air Force Military Medical University; The First Affiliated Hospital of the Air Force Military Medical University

P=N/A, N=0, Not yet recruiting, Northern Jiangsu People's Hospital; Northern Jiangsu People's Hospital

P=N/A, N=400, Not yet recruiting, The forth Hospital of Hebei Medical University; Forth Hospital of Hebei Medical University

P=N/A, N=0, Recruiting, Henan Provincial People's Hospital; Henan Provincial People's Hospital

P=N/A, N=70, Not yet recruiting, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medi

P=N/A, N=116, Recruiting, Affiliated Hospital of Jiangsu University; Affiliated Hospital of Jiangsu University

P=N/A, N=0, Recruiting, Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College

P=N/A, N=107, Not yet recruiting, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University; The First Affiliated Hospital of Nanjing Medical Universit

P=N/A, N=1101, Completed, Beijing University Cancer Hospital; Beijing University Cancer Hospital

P=N/A, N=0, Not yet recruiting, The First Affliliated Hospital of the Air Force Medical University; The First Affliliated Hospital,the Air Force Medical University

P=N/A, N=240, Completed, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medi

P=N/A, N=60, Recruiting, The Third Affiliated Hospital of Sun Yat sen University; The Third Affiliated Hospital of Sun Yat sen University

P=N/A, N=200, Not yet recruiting, Shanxi Bethune Hospital Shanxi Academy of Medical Sciences; Shanxi Bethune Hospital Shanxi Academy of Medical Sciences

P=N/A, N=0, Not yet recruiting, Northern Jiangsu People's Hospital; Northern Jiangsu People's Hospital

P=N/A, N=20, Not yet recruiting, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medi

P4, N=74, Completed, Changzhi People's Hospital; Changzhi People's Hospital

P4, N=90, Not yet recruiting, Tangdu Hospital, Air Force Medical University; Tangdu Hospital, Air Force Medical University

P2, N=130, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of

P1, N=30, Not yet recruiting, he Second Affiliated Hosipital of Chongqing Medical University; The Second Affiliated Hosipital of Chongqing Medical University

P=N/A, N=50, Not yet recruiting, Varian, a Siemens Healthineers Company

P=N/A, N=72, Completed, Kantonsspital Winterthur KSW | Recruiting --> Completed | Trial completion date: Jun 2024 --> Nov 2024 | Trial primary completion date: Jun 2024 --> Sep 2024

P2, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

P=N/A, N=1650, Recruiting, Portsmouth Hospitals NHS Trust | Trial completion date: Jun 2023 --> Jun 2026 | Trial primary completion date: Jun 2023 --> Jun 2026

P=N/A, N=22, Terminated, Institut Cancerologie de l'Ouest | N=100 --> 22 | Trial completion date: Sep 2024 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2024 --> Mar 2024; lack of patient enrolment

Activation of Nrf2 signaling by LR HCC cell-derived exosomal miR-301a-3p skewed the transformation of macrophages to the M2 phenotype. Our study provides new findings on the role of miR-301a-3p, suggesting it is a promising therapeutic target to improve HCC lenvatinib resistance.

However, these potential roles of K18 in tumors have not been fully summarized. In this review, we focus on the relationship between K18 and epithelial-derived tumors, discuss the value of K18 as a diagnostic and prognostic marker, and summarize the interactions of K18 with various related proteins in tumorigenesis, with examples of simple epithelial tumors such as lung, breast, liver, and gastrointestinal cancers.

P=N/A, N=19, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting

Furthermore, there was a significant increase in apoptosis induction and in caspase-3 activity in cancer cells treated with L. plantarum and bacteriocin compared to untreated cells. In conclusion, L. plantarum and its bacteriocin show potent killing effect against esophageal cancer cells with no effect against normal cells indicating safety and selectivity with activation of apoptosis via caspase-3 induction suggesting potential clinical advantage.

She was successfully treated with surgical resection and anastomosis. Histopathology, immunohistochemistry (diffuse positivity for S100 and weak positivity for synaptophysin) and molecular fluorescence in-situ hybridization (FISH) study (translocation involving the chromosomal region 2212.1-q12.2 which harbors EWSR1 gene) confirmed the diagnosis of GNET.

Accordingly, IGFBP1 may function as a tumor suppressor gene, while H3R117 MARylation may promote CRC development. Our study findings enrich the available data on epigenetics of CRC and provide a new idea and experimental basis for H3R117 MARylation as a target in CRC treatment.

MFGE8 promoted cell proliferation, EMT progress, and tumor growth of gastric cancer by activating the IL-6/JAK/STAT3 signaling.

In GC cell cytoplasm, the ISL1-ANXA2 complex synergistically activates matrix metalloproteinases, thus promoting cell migration. In conclusion, ISL1 is a potential therapeutic target for GC.

A radiomics nomogram based on T2WI and ADC sequences and clinicopathologic features can effectively and noninvasively predict the MSI status in CRC. This approach helps clinicians in stratifying CRC patients and making clinical decisions for personalized treatment.

Notably, the review concludes with a summary of the recent applications of targeting ZBTB7A in clinical treatments through gene silencing, immunotherapy and chemotherapeutic approaches to halt or slow tumor progression. We focus on the functional role and regulatory mechanisms of ZBTB7A in cancer with the goal of providing new insights for the development of more effective cancer therapeutic strategies.

We furtherly described that KLB exhibits protective effects against metabolic disorders by acting in an FGF-dependent and independent manner thus triggering the hypothesis that KLB soluble forms may play a critical role in preserving liver health. Therefore, targeting KLB may provide promising strategies for treating MASLD, as supported by experimental evidence and ongoing clinical trials.

Additionally, [Cu(L1)₂] is equally active on gastric cancer stem cells and tumor cells resistant to cisplatin. More importantly, stem cells treated with [Cu(L1)₂] show a downregulation of pluripotency markers such as TWIST, NANOG and OCT4. Overall, our results with [Cu(L1)₂] prompt a significant advancement in the development of rational-designed pharmaceuticals for combating cancer.